Fulton Bank N.A. Purchases 14,658 Shares of Sanofi $SNY

Fulton Bank N.A. boosted its position in Sanofi (NASDAQ:SNY) by 29.4% during the 1st quarter, according to its most recent Form 13F filing with the SEC. The fund owned 64,573 shares of the company’s stock after purchasing an additional 14,658 shares during the period. Fulton Bank N.A.’s holdings in Sanofi were worth $3,111,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Intrua Financial LLC purchased a new position in shares of Sanofi in the first quarter worth approximately $209,000. Fairway Wealth LLC purchased a new stake in Sanofi during the first quarter valued at approximately $32,000. Apollon Wealth Management LLC raised its position in Sanofi by 44.4% in the first quarter. Apollon Wealth Management LLC now owns 14,503 shares of the company’s stock worth $699,000 after acquiring an additional 4,458 shares during the period. BKM Wealth Management LLC boosted its stake in shares of Sanofi by 25.4% during the 1st quarter. BKM Wealth Management LLC now owns 13,310 shares of the company’s stock worth $641,000 after acquiring an additional 2,700 shares during the last quarter. Finally, Larry Mathis Financial Planning LLC purchased a new position in shares of Sanofi during the 1st quarter worth $216,000. Hedge funds and other institutional investors own 14.03% of the company’s stock.

Analyst Ratings Changes

SNY has been the subject of several analyst reports. Weiss Ratings upgraded Sanofi from a “sell (d+)” rating to a “hold (c-)” rating in a research note on Wednesday, May 13th. BNP Paribas Exane downgraded Sanofi from an “outperform” rating to a “neutral” rating and set a $50.00 target price on the stock. in a research report on Monday, April 20th. Argus raised Sanofi to a “strong-buy” rating in a report on Monday, April 27th. Sanford C. Bernstein upgraded Sanofi to a “strong-buy” rating in a research report on Thursday, March 19th. Finally, Morgan Stanley set a $52.00 price objective on Sanofi in a research note on Friday, May 1st. Two analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating and ten have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus target price of $51.00.

Sanofi Stock Performance

Shares of NASDAQ SNY opened at $41.63 on Thursday. The firm has a fifty day moving average price of $43.84 and a 200-day moving average price of $45.90. The company has a debt-to-equity ratio of 0.17, a current ratio of 1.01 and a quick ratio of 0.22. The stock has a market cap of $100.93 billion, a PE ratio of 11.63, a price-to-earnings-growth ratio of 1.05 and a beta of 0.35. Sanofi has a 1 year low of $40.89 and a 1 year high of $52.68.

Sanofi Increases Dividend

The firm also recently declared an annual dividend, which was paid on Wednesday, June 3rd. Shareholders of record on Monday, May 4th were issued a dividend of $2.4225 per share. This is a boost from Sanofi’s previous annual dividend of $2.04. This represents a yield of 559.0%. The ex-dividend date of this dividend was Monday, May 4th. Sanofi’s payout ratio is 49.16%.

Sanofi Profile

Sanofi (NASDAQ:SNY) is a multinational pharmaceutical company headquartered in France that researches, develops, manufactures and markets prescription medicines, vaccines and consumer healthcare products. The company operates across multiple therapeutic areas, including immunology, rare diseases, oncology, cardiovascular and metabolic diseases, and vaccines through its Sanofi Pasteur division. Sanofi sells products to hospitals, clinics, governments and retail pharmacies, with a broad global footprint and significant presence in Europe, North America and emerging markets.

Key commercial offerings include specialty biologics and established small-molecule medicines.